Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
July 2022
Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus
Dörner T, et al. Ann Rheum Dis. 2022. Epub ahead of print. doi:10.1136/annrheumdis-2022-222335.
Phase II study results suggest that baricitinib 4 mg downregulates key cytokines that are upregulated in patients with SLE.
June 2022
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
Rheumatology (Oxford). 2022;61(6):2413–2423 doi: 10.1093/rheumatology/keab685
Proof-of-concept study for the safety and efficacy of filgotinib (FIL) and lanraplenib (LANRA) in cutaneous lupus (CLE) fails to meet primary endpoint, but select subgroups displayed a numerically greater treatment response to FIL relative to placebo.
Baricitinib decreases anti‑dsDNA in patients with systemic lupus erythematosus: results from a phase II double‑blind, randomized, placebo‑controlled trial
Arthritis Res Ther 2022;24(1):112 doi: 10.1186/s13075-022-02794-x
Evaluation of serological activity, including antibodies against double-stranded DNA (anti-dsDNA), suggests that baricitinib may influence B cell activity in systemic lupus erythematosus (SLE).
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
Ann Rheum Dis 2022;81:962–969 doi: 10.1136/annrheumdis-2021-221847
Bruce, et al. investigate the degree of concordance between BICLA and SRI-4 response across anifrolumab trials (TULIP-1, TULIP-2 and MUSE) in order to better understand drivers of discrepant systemic lupus erythematosus (SLE) trial results.
Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
J Comp Eff Res. 2022;11(10):765–777 doi: 10.2217/cer-2022-0040
Population-adjusted comparative study provides insights for decision makers and clinicians about the comparative efficacy of anifrolumab and belimumab in patients with moderate-to-severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
In the absence of head-to-head comparisons, Bruce, et al. assessed the comparative efficacy of the two biological therapies currently approved in the EU and USA for the treatment of moderate-to-severe SLE (anifrolumab 300 mg and belimumab 10 mg/kg).
After adjusting for important cross-trial differences, their results showed that anifrolumab was associated with significantly greater treatment benefits than belimumab.
Biological impact of iberdomide in patients with active systemic lupus erythematosus
doi: 10.1136/annrheumdis-2022-222212
Phase 2b study evaluating the pharmacodynamics and pharmacokinetics of oral iberdomide in patients with active SLE demonstrates that iberdomide significantly improves lupus disease activity and reduces hallmarks of the immunopathogenesis of SLE.
Keywords:
May 2022
Impact of belimumab on organ damage in systemic lupus erythematosus
Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24901
Review of clinical trial and real-world data on the effects of belimumab on organ damage in adult patients with SLE shows that belimumab reduces key drivers of organ damage, decreases organ damage progression and, in those with lupus nephritis (LN), decreases renal-related events.
Keywords:
Race, Ethnicity, and Disparities in Risk of End-organ Lupus Manifestations Following SLE Diagnosis in a Multiethnic Cohort
Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24892
California Lupus Epidemiology Study (CLUES) finds heightened risks of developing renal, haematologic, and multiorgan disease following SLE diagnosis among Hispanic and Asian patients with SLE.
Keywords:
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study Over a 41+ Year Period
Rheumatology (Oxford). 2022 Epub ahead of print
Retrospective observational study over a 41-year period finds complete remission (CR) in SLE to be associated with Caucasian race, older age at diagnosis, absence of renal involvement and absence of antiphospholipid syndrome.
High Systemic Type I Interferon Activity Is Associated with Active Class III/IV Lupus Nephritis
The Journal of Rheumatology 2022; 49:388–97 DOI 10.3899/jrheum.210391
Iwamoto, et al. aimed to determine the association of serum IFN activity with subtypes of lupus nephritis. This study suggests that systemic high type I IFN in SLE is involved in the pathogenesis of severe class III/IV LN and contributes to severe kidney involvement in European-American patients with SLE. However, this effect was independent of anti‑dsDNA antibody status and complement levels. Expression of type I IFN was not found to be clearly related to plasmacytoid dendritic cell infiltration, although it did directly stimulate podocytes to induce chemokines and molecules related to podocyte injury.